Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$7.27 CAD
Change Today -0.18 / -2.42%
Volume 385.0
As of 4:10 PM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

aptose biosciences inc (APS) Snapshot

Open
C$7.54
Previous Close
C$7.45
Day High
C$7.54
Day Low
C$7.27
52 Week High
10/29/14 - C$9.14
52 Week Low
08/20/14 - C$4.80
Market Cap
86.3M
Average Volume 10 Days
14.5K
EPS TTM
--
Shares Outstanding
11.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for APTOSE BIOSCIENCES INC (APS)

Related News

No related news articles were found.

aptose biosciences inc (APS) Related Businessweek News

No Related Businessweek News Found

aptose biosciences inc (APS) Details

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, a small molecule that induces the transcription of the Krüppel-like factor 4 Gene in in vitro studies and in in vivo pharmacodynamic studies of human xenograft tumors in mice. The company’s APTO-253 clinical program has completed Phase-I clinical trials for the treatment of various solid tumors; and Phase-Ib clinical trials for relapsed/refractory hematologic malignancies. It also develops APTO-500 program that focuses on discovering and developing small molecule inhibitors of maternal embryonic leucine zipper kinase; and is in a pre-clinical stage for oncology. In addition, the company develops small molecule program, which is in pre-clinical stage for various indications; and early discovery program that is in discovery stage for various indications. It has a license agreement with Genentech Inc. to develop and sub-license a specified polypeptide; and collaboration agreement with Eli Lilly and Company to investigate a proprietary series of the company’s compounds for veterinary medicine. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.

18 Employees
Last Reported Date: 03/4/15
Founded in 1986

aptose biosciences inc (APS) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: C$321.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: C$201.6K
Chief Business Officer and Senior Vice Presid...
Total Annual Compensation: C$201.6K
Vice President of Research
Total Annual Compensation: C$141.1K
Compensation as of Fiscal Year 2014.

aptose biosciences inc (APS) Key Developments

Aptose Biosciences Inc. Proposes Amendment to the Articles of the Company

Aptose Biosciences Inc. proposed a special resolution, approving an amendment to the articles of the company to expand the places where meetings of the shareholders of the company may be held to include certain cities in the United States and Europe, at its annual and special meeting of shareholders will be held on June 10, 2015.

Aptose Biosciences Inc. Reports Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Aptose Biosciences Inc. reported consolidated unaudited earnings results for the first quarter ended March 31, 2015. Net loss and total comprehensive loss for the period was CAD 3,569,000 against CAD 2,433,000 a year ago. Basic and diluted loss per common share was CAD 0.30 against CAD 0.48 per share a year ago. The increase in net loss is due to higher research and development costs associated with increased clinical activity on APTO-253 and associated activities as well as increased general and administrative costs associated with higher stock-based compensation costs and expenses related to the NASDAQ listing, prospectus supplement and related costs, the expense of relocating the Toronto facilities and other corporate activities. Cash used in operating activities was CAD 2,223,000 against CAD 2,191,000 a year ago.

Aptose Biosciences Inc., Q1 2015 Earnings Call, May 05, 2015

Aptose Biosciences Inc., Q1 2015 Earnings Call, May 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APS:CN C$7.27 CAD -0.18

APS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for APS.
View Industry Companies
 

Industry Analysis

APS

Industry Average

Valuation APS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.3x
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact APTOSE BIOSCIENCES INC, please visit www.aptose.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.